{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-061994","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.118427+00:00","generated_at":"2026-05-23T01:29:03.630364+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"medium","headline":"Perspective Therapeutics updates corporate presentation on 212Pb radiopharmaceutical pipeline","bullets":["Neuroendocrine tumor trial VMT-α-NET Phase 1/2a shows sustained anti-tumor activity and good tolerability; no renal function decline observed.","Metastatic melanoma program VMT01/02 Phase 1/2a dosing ongoing; treatment-emergent AEs summarized in presentation.","PSV359 Phase 1/2a targets FAP-α expression on tumor and stroma.","Platform uses proprietary chelator optimized for lead-212 RPTs and on-demand regional manufacturing infrastructure."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-061994","json":"https://secwatch.observer/filing/0000950170-25-061994.json","markdown":"https://secwatch.observer/filing/0000950170-25-061994.md","text":"https://secwatch.observer/filing/0000950170-25-061994.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017025061994/0000950170-25-061994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017025061994/catx-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:29:03.630364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}